Report Detail

Pharma & Healthcare Global Adalimumab Biosimilar Market Research Report 2019 by Manufacturers, Regions, Types and Applications

  • RnM3513210
  • |
  • 03 August, 2020
  • |
  • Global
  • |
  • 116 Pages
  • |
  • XYZResearch
  • |
  • Pharma & Healthcare

According to XYZResearch study, over the next five years the Adalimumab Biosimilarmarket will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026, from US$ xx million in 2020. In particular, this report presents the global market share (sales and revenue) of key companies in Adalimumab Biosimilarbusiness.
Adalimumab Biosimilar market development trend, sales volume and sales value (million USD) forecast in regional market, the main regions are China, USA, Europe, India, Japan, Korea, South America, Southeast Asia.
Sales forecast by type/application from 2021-2026
Industry chain, downstream and upstream information is also included.
World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war.
Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO. The decline in exports has been mainly due to the ongoing global slowdown, which got aggravated due to the current Covid-19 crisis. The latter resulted in large scale disruptions in supply chains and demand resulting in cancellation of orders.
XYZResearch’s analysis shows that as China started reopening its economy, world exports initially recovered across the board. But estimates of the expected recovery in 2021 are uncertain, with outcomes depending largely on the duration of the outbreak and the effectiveness of the policy responses.

This report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Adalimumab Biosimilar for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America

Global Adalimumab Biosimilar market competition by top manufacturers/players, with Adalimumab Biosimilar sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
AET BioTech
Amgen
Boehringer Ingelheim
Coherus Biosciences
Fujifilm Kyowa Kirin Biologics
LG Life Sciences/Mochida Pharmaceutical
Momenta Pharmaceuticals
Oncobiologics
Pfizer
Samsung Bioepsis
Sandoz
Zydus Cadila
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Tablet
Oral Solution
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Adalimumab Biosimilar for each application, including
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Feel free to let me know if you have any special requirements.


Table of Contents

    1 Executive Summary

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Adalimumab Biosimilar Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Tablet
      • 2.1.2 Oral Solution
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 Tablet
      • 2.2.2 Oral Solution

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospital Pharmacy
      • 3.1.2 Retail Pharmacy
      • 3.1.3 Online Pharmacy

    4 Manufacturers Profiles/Analysis

    • 4.1 AET BioTech
      • 4.1.1 AET BioTech Profiles
      • 4.1.2 AET BioTech Product Information
      • 4.1.3 AET BioTech Adalimumab Biosimilar Sales, Sales Value(Million USD), Price and Gross Profit
      • 4.1.4 AET BioTech SWOT Analysis
    • 4.2 Amgen
      • 4.2.1 Amgen Profiles
      • 4.2.2 Amgen Product Information
      • 4.2.3 Amgen Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.2.4 Amgen SWOT Analysis
    • 4.3 Boehringer Ingelheim
      • 4.3.1 Boehringer Ingelheim Profiles
      • 4.3.2 Boehringer Ingelheim Product Information
      • 4.3.3 Boehringer Ingelheim Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.3.4 Boehringer Ingelheim SWOT Analysis
    • 4.4 Coherus Biosciences
      • 4.4.1 Coherus Biosciences Profiles
      • 4.4.2 Coherus Biosciences Product Information
      • 4.4.3 Coherus Biosciences Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.4.4 Coherus Biosciences SWOT Analysis
    • 4.5 Fujifilm Kyowa Kirin Biologics
      • 4.5.1 Fujifilm Kyowa Kirin Biologics Profiles
      • 4.5.2 Fujifilm Kyowa Kirin Biologics Product Information
      • 4.5.3 Fujifilm Kyowa Kirin Biologics Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.5.4 Fujifilm Kyowa Kirin Biologics SWOT Analysis
    • 4.6 LG Life Sciences/Mochida Pharmaceutical
      • 4.6.1 LG Life Sciences/Mochida Pharmaceutical Profiles
      • 4.6.2 LG Life Sciences/Mochida Pharmaceutical Product Information
      • 4.6.3 LG Life Sciences/Mochida Pharmaceutical Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.6.4 LG Life Sciences/Mochida Pharmaceutical SWOT Analysis
    • 4.7 Momenta Pharmaceuticals
      • 4.7.1 Momenta Pharmaceuticals Profiles
      • 4.7.2 Momenta Pharmaceuticals Product Information
      • 4.7.3 Momenta Pharmaceuticals Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.7.4 Momenta Pharmaceuticals SWOT Analysis
    • 4.8 Oncobiologics
      • 4.8.1 Oncobiologics Profiles
      • 4.8.2 Oncobiologics Product Information
      • 4.8.3 Oncobiologics Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.8.4 Oncobiologics SWOT Analysis
    • 4.9 Pfizer
      • 4.9.1 Pfizer Profiles
      • 4.9.2 Pfizer Product Information
      • 4.9.3 Pfizer Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.9.4 Pfizer SWOT Analysis
    • 4.10 Samsung Bioepsis
      • 4.10.1 Samsung Bioepsis Profiles
      • 4.10.2 Samsung Bioepsis Product Information
      • 4.10.3 Samsung Bioepsis Adalimumab BiosimilarSales, Sales Value (Million USD), Price and Gross Profit
      • 4.10.4 Samsung Bioepsis SWOT Analysis
    • 4.11 Sandoz
    • 4.12 Zydus Cadila

    5 Market Performance for Manufacturers

    • 5.1 Global Adalimumab Biosimilar Sales (K Units) and Market Share by Manufacturers 2014-2020
    • 5.2 Global Adalimumab Biosimilar Revenue (M USD) and Market Share by Manufacturers 2014-2020
    • 5.3 Global Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
    • 5.4 Global Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.1.2 China Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.1.3 China Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.1.4 China Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.1.5 Market Concentration
    • 6.2 USA Market Performance for Manufacturers
      • 6.2.1 USA Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.2.2 USA Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.2.3 USA Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.2.4 USA Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.2.5 Market Concentration
    • 6.3 Europe Market Performance for Manufacturers
      • 6.3.1 Europe Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.3.2 Europe Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.3.3 Europe Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.3.4 Europe Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.3.5 Market Concentration
    • 6.4 Japan Market Performance for Manufacturers
      • 6.4.1 Japan Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.4.2 Japan Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.4.3 Japan Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.4.4 Japan Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.4.5 Market Concentration
    • 6.5 Korea Market Performance for Manufacturers
      • 6.5.1 Korea Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.5.2 Korea Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.5.3 Korea Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.5.4 Korea Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.5.5 Market Concentration
    • 6.6 India Market Performance for Manufacturers
      • 6.6.1 India Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.6.2 India Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.6.3 India Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.6.4 India Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.6.5 Market Concentration
    • 6.7 Southeast Asia Market Performance for Manufacturers
      • 6.7.1 Southeast Asia Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.7.2 Southeast Asia Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.7.3 Southeast Asia Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.7.4 Southeast Asia Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.7.5 Market Concentration
    • 6.8 South America Market Performance for Manufacturers
      • 6.8.1 South America Adalimumab Biosimilar Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.8.2 South America Adalimumab Biosimilar Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.8.3 South America Adalimumab Biosimilar Price (USD/Unit) of Manufacturers 2014-2020
      • 6.8.4 South America Adalimumab Biosimilar Gross Margin of Manufacturers 2014-2020
      • 6.8.5 Market Concentration

    7 Global Adalimumab Biosimilar Market Assessment by Regions (2014-2020)

    • 7.1 Global Adalimumab Biosimilar Sales (K Units) and Market Share by Regions 2014-2020
    • 7.2 Global Adalimumab Biosimilar Revenue (M USD) and Market Share by Regions 2014-2020
    • 7.3 Global Adalimumab Biosimilar Price (USD/Unit) by Regions 2014-2020
    • 7.4 Global Adalimumab Biosimilar Gross Margin by Regions 2014-2020

    8 Development Trend for Regions

    • 8.1 Global Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.2 China Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.3 USA Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.4 Europe Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.5 Japan Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.6 Korea Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.7 India Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.8 Southeast Asia Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.8 Southeast Asia Adalimumab Biosimilar Sales and Growth, Sales Value and Growth Rate 2014-2020

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Manufacturing Plants Distribution

    11 Consumer Analysis

    • 11.1 Hospital Pharmacy Industry
    • 11.2 Retail Pharmacy Industry
    • 11.3 Online Pharmacy Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 Global Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 Global Adalimumab Biosimilar Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 China Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 USA Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 Europe Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 Japan Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 Korea Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 India Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.9 Southeast Asia Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.10 South America Adalimumab Biosimilar Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2021-2026
      • 12.2.1 Overall Market Performance
      • 12.2.2 Tablet
      • 12.2.3 Oral Solution
    • 12.3 Sales (K Units) Forecast by Application 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 Hospital Pharmacy
      • 12.3.3 Retail Pharmacy
      • 12.3.4 Online Pharmacy
    • 12.4 Price (USD/Unit) and Gross Profit
      • 12.4.1 Global Adalimumab Biosimilar Price (USD/Unit) Trend 2021-2026
      • 12.4.2 Global Adalimumab Biosimilar Gross Profit Trend 2021-2026

    13 Conclusion

    Summary:
    Get latest Market Research Reports on Adalimumab Biosimilar. Industry analysis & Market Report on Adalimumab Biosimilar is a syndicated market report, published as Global Adalimumab Biosimilar Market Research Report 2019 by Manufacturers, Regions, Types and Applications. It is complete Research Study and Industry Analysis of Adalimumab Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,650.00
    $7,200.00
    2,890.80
    5,702.40
    3,372.60
    6,652.80
    552,208.50
    1,089,288.00
    304,300.50
    600,264.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report